Agios reports Q3 2026 results, revenue jumps and FDA extends sickle‑cell review
Agios Pharmaceuticals announced third‑quarter 2026 net revenue of $55.4 million, a more than four‑fold increase from the same quarter a year earlier, driven by U.S. demand for AQVESME in thalassemia. The company posted a net loss of $65.0 million, narrower than the $103.4 million loss in Q3 2025. The FDA moved the PDUFA decision date for the mitapivat sickle‑cell disease supplemental NDA to February 1 2027.
Why it matters
The sharper loss and strong cash balance of $907.0 million give Agios runway to fund commercial launches and its target of non‑GAAP profitability in 2028 (source 2). The FDA’s extension pushes back potential revenue from a sickle‑cell indication to 2027, affecting timing of future growth (source 9).
Key facts
- 1Worldwide net revenue from mitapivat products was $55.4 million in Q3 2026, up from $12.9 million in Q3 2025. stocktitan.net
- 2Net loss for the quarter was $65.0 million, improved from $103.4 million a year earlier. tradingview.com
- 3Cash, cash equivalents and marketable securities totaled $907.0 million as of September 30 2026. stocktitan.net
- 4Cumulative AQVESME prescriptions with completed start forms reached 619 as of September 30 2026. stocktitan.net
- 5The FDA extended the PDUFA goal date for the mitapivat sickle‑cell disease sNDA to February 1 2027. stocktitan.net
- 6Agios targets non‑GAAP profitability in 2028. stocktitan.net
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.